{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:47Z","timestamp":1794046487610,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The PRODIGE7 trial demonstrated a lack of effectiveness of oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for colorectal cancer peritoneal metastases (CRC-PM), prompting many centers to transition to mitomycin C (MMC)-based HIPEC. However, the oncologic benefit of MMC-HIPEC remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 2021, our\u00a0 center systematically discontinued HIPEC for CRC-PM. We\u00a0 retrospectively compared consecutive patients who underwent MMC-HIPEC after complete CRS (2009\u20132021) with those undergoing CRS alone (2021\u20132024). Outcomes included recurrence-free survival (RFS), peritoneal RFS, and 90-day postoperative outcomes. Propensity score-matching was performed using age, sex, primary tumor location, extraperitoneal disease, completeness of cytoreduction score, peritoneal carcinomatosis index, and preoperative chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The\u00a0study included 107 consecutive patients (median age, 56 years; median peritoneal carcinomatosis index [PCI], 8; 48% male; 45% left-sided primary tumor), 68 (64%) of whom underwent CRS-HIPEC with MMC. Most of the patients (75%) experienced recurrence. After matching, 96 patients remained (32 treated with CRS alone; 64 treated with CRS-HIPEC). Between CRS alone and CRS-HIPEC, RFS was comparable (median, 8.4 months [95% confidence interval {CI}, 5.6\u201312.7 months] vs. 8.7 months [95% CI, 6.2\u201311.0 months];\n                      <jats:italic>p<\/jats:italic>\n                      = 0.527), as was peritoneal RFS (median 12.7 months [95% CI, 8.4\u2013not reached {NR}] vs. 14.2 [95% CI, 8.7\u201319.8 months];\n                      <jats:italic>p<\/jats:italic>\n                      = 0.806). The CRS-HIPEC patients had more respiratory complications (0% vs. 13%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.037) and longer hospital stays (median, 10 vs. 7 days;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Exploratory analyses suggested benefit in node-negative disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Omission of MMC-HIPEC did not compromise oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20689-y","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:43:08Z","timestamp":1791387788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Systematic Discontinuation of Mitomycin C HIPEC for Colorectal Peritoneal Metastases on Oncologic Outcomes: A Propensity Score-Matched Analysis"],"prefix":"10.1245","author":[{"given":"M. Daniyal","family":"Tanweer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Talha","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac B.","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinzar","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pashtoon Murtaza","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"20689_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LGM van der Geest","year":"2015","unstructured":"van der Geest LGM, Lam-Boer J, Koopman M, Verhoef C, Elferink MAG, de Wilt JHW. Nationwide trends in incidence, treatment. and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32:457\u201365.","journal-title":"Clin Exp Metastasis."},{"key":"20689_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.soc.2018.02.011","volume":"27","author":"D Go\u00e9r\u00e9","year":"2018","unstructured":"Go\u00e9r\u00e9 D, Sourrouille I, Gelli M, Benhaim L, Faron M, Honor\u00e9 C. Peritoneal metastases from colorectal cancer. Surg Oncol Clin North Am. 2018;27:563\u201383.","journal-title":"Surg Oncol Clin North Am."},{"key":"20689_CR3","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.","journal-title":"Lancet Oncol."},{"key":"20689_CR4","first-page":"60","volume":"84","author":"T Fujimura","year":"1999","unstructured":"Fujimura T, Yonemura Y, Fujita H, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg. 1999;84:60\u20136.","journal-title":"Int Surg."},{"key":"20689_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U","volume":"14","author":"PH Sugarbaker","year":"1998","unstructured":"Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254\u201361.","journal-title":"Semin Surg Oncol."},{"key":"20689_CR6","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284\u201392.","journal-title":"J Clin Oncol."},{"key":"20689_CR7","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, Van Ruth S, De Bree E, Van Slooten GW, Van Tinteren H, Boot H, Zoetmulder FAN. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.","journal-title":"J Clin Oncol."},{"key":"20689_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256\u201366.","journal-title":"Lancet Oncol."},{"key":"20689_CR9","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe SD, Sasikumar S, Moaven O, Sivakumar H, Shen P, Levine EA, et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27:4950\u201360.","journal-title":"Ann Surg Oncol."},{"key":"20689_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","volume":"31","author":"M H\u00fcbner","year":"2024","unstructured":"H\u00fcbner M, van Der Speeten K, Govaerts K, de Hingh I, Villeneuve L, Kusamura S, Glehen O. 2022 Peritoneal Surface Oncology Group international consensus on HIPEC regimens for peritoneal malignancies: colorectal cancer. Ann Surg Oncol. 2024;31:567\u201376.","journal-title":"Ann Surg Oncol."},{"key":"20689_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/02656736.2017.1367846","volume":"34","author":"M Alyami","year":"2018","unstructured":"Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, K\u00e9p\u00e9n\u00e9kian V, Bakrin N, et al. Ninety-day postoperative morbidity and mortality using the National Cancer Institute\u2019s common terminology criteria for adverse events better describe postoperative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34:532\u20137.","journal-title":"Int J Hyperthermia."},{"key":"20689_CR12","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.3390\/jcm11164922","volume":"11","author":"F Mendoza-Moreno","year":"2022","unstructured":"Mendoza-Moreno F, Diez-Alonso M, Mat\u00edas-Garc\u00eda B, et al. Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer. J Clin Med. 2022;11:4922.","journal-title":"J Clin Med."},{"key":"20689_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13193-016-0505-5","volume":"7","author":"SS Mehta","year":"2016","unstructured":"Mehta SS, Bhatt A, Glehen O. Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol. 2016;7:139\u201351.","journal-title":"Indian J Surg Oncol."},{"key":"20689_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jss.2025.01.016","volume":"307","author":"MT Waheed","year":"2025","unstructured":"Waheed MT, Hernandez MC, Malik I, et al. Feasibility of robotic surgical approach in peritoneal carcinomatosis. J Surg Res. 2025;307:70\u20137.","journal-title":"J Surg Res."},{"key":"20689_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol."},{"key":"20689_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"DB Rubin","year":"2001","unstructured":"Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169\u201388.","journal-title":"Health Serv Outcomes Res Methodol."},{"key":"20689_CR17","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1177\/0962280220921889","volume":"29","author":"TA Balan","year":"2020","unstructured":"Balan TA, Putter H. A tutorial on frailty models. Stat Methods Med Res. 2020;29:3424\u201354.","journal-title":"Stat Methods Med Res."},{"key":"20689_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681\u20135.","journal-title":"J Clin Oncol."},{"key":"20689_CR19","doi-asserted-by":"publisher","first-page":"101676","DOI":"10.1016\/j.suronc.2021.101676","volume":"40","author":"H Abdel Mageed","year":"2022","unstructured":"Abdel Mageed H, Van Der Speeten K, Sugarbaker P. The many faces of intraperitoneal chemotherapy. Surg Oncol. 2022;40:101676.","journal-title":"Surg Oncol."},{"key":"20689_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/jcm7120567","volume":"7","author":"C Yurttas","year":"2018","unstructured":"Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, K\u00f6nigsrainer I, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 2018;7:567.","journal-title":"J Clin Med."},{"key":"20689_CR21","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","volume":"46","author":"C Bakkers","year":"2020","unstructured":"Bakkers C, Van Erning FN, Rovers KP, et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study. Eur J Surg Oncol. 2020;46:1902\u20137.","journal-title":"Eur J Surg Oncol."},{"key":"20689_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/bjs5.50250","volume":"4","author":"FMK Elekonawo","year":"2020","unstructured":"Elekonawo FMK, Eden WJ, Plas WY, et al. Effect of intraperitoneal chemotherapy concentration on morbidity and survival. BJS Open. 2020;4:293\u2013300.","journal-title":"BJS Open."},{"key":"20689_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779\u201385.","journal-title":"J Surg Oncol."},{"key":"20689_CR24","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00384-020-03702-y","volume":"35","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wu Q, Wei M, Deng X, Gu C, Wang Z. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. Int J Colorectal Dis. 2020;35:1831\u20139.","journal-title":"Int J Colorectal Dis."},{"key":"20689_CR25","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1245\/s10434-025-17651-9","volume":"32","author":"JM Foster","year":"2025","unstructured":"Foster JM, Nash GM, M\u00f6ller MG. Great debate: hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: should it be offered? Ann Surg Oncol. 2025;32:6215\u201322.","journal-title":"Ann Surg Oncol."},{"key":"20689_CR26","first-page":"49","volume":"73","author":"JM Foster","year":"2023","unstructured":"Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin. 2023;73:49\u201371.","journal-title":"CA Cancer J Clin."},{"key":"20689_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:761\u201370.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20689_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-022-09572-7","volume":"22","author":"F Pereira","year":"2022","unstructured":"Pereira F, Serrano A, Manzanedo I, et al. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer. 2022;22:536.","journal-title":"BMC Cancer."},{"key":"20689_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.23546","volume":"109","author":"D Hompes","year":"2014","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109:527\u201332.","journal-title":"J Surg Oncol."},{"key":"20689_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","volume":"44","author":"WJ Van Eden","year":"2018","unstructured":"Van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44:220\u20137.","journal-title":"Eur J Surg Oncol."},{"key":"20689_CR31","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367.","journal-title":"N Engl J Med."},{"key":"20689_CR32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu R-H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319:2486\u201396.","journal-title":"JAMA."},{"key":"20689_CR33","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Colon Cancer (2017)."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20689-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:43:09Z","timestamp":1791387789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20689-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":33,"alternative-id":["20689"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20689-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}